Sector Expert: Shane Storey
Shane Storey joined Wilson HTM Investment Group in late 2007 as a senior research analyst, covering healthcare, pharmaceuticals, medical devices and biotechnology. He is now head of research. Storey has nearly 20 years experience in these fields, as a molecular biologist, process engineer, consultant, venture capital financier and senior executive. Before joining Wilson HTM, Storey managed investments for one of Australia's first venture capital funds to specialize to emerging Australian biotechnology companies. The fund outperformed the top quartile returns from U.S. venture funds of an equivalent vintage. Storey holds bachelor's degrees in science and chemical engineering from the University of Queensland, a Ph.D. in biochemical engineering from University College London, and a master's degree in business administration from the Macquarie Graduate School of Management.
Australia will always be known as a trove of natural resources, but its most precious treasure is the abundance of entrepreneurs who are all too happy to develop the country's intellectual assets. Shane Storey, head of research at Australia-based Wilson HTM Investment Group, observes that as the market value of resource commodities declines, investors are diverting investment capital to healthcare stocks, especially in the medical technology sector. In this interview with The Life Sciences Report, Storey presents three names that don't come close to their long-term fair valuation potential. The upside, he believes, could be quite dramatic.
"IPD's business model is one we know and love; there is a lot of upside in this company."
The Life Sciences Report Interview with Shane Storey